These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12615650)

  • 1. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.
    Squitieri F; Gellera C; Cannella M; Mariotti C; Cislaghi G; Rubinsztein DC; Almqvist EW; Turner D; Bachoud-Lévi AC; Simpson SA; Delatycki M; Maglione V; Hayden MR; Donato SD
    Brain; 2003 Apr; 126(Pt 4):946-55. PubMed ID: 12615650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical manifestations of homozygote allele carriers in Huntington disease.
    Cubo E; Martinez-Horta SI; Santalo FS; Descalls AM; Calvo S; Gil-Polo C; Muñoz I; Llano K; Mariscal N; Diaz D; Gutierrez A; Aguado L; Ramos-Arroyo MA;
    Neurology; 2019 Apr; 92(18):e2101-e2108. PubMed ID: 30867264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygote of spinocerebellar Ataxia type 3 correlating with severe phenotype based on analyses of clinical features.
    Shang XJ; Xu HL; Yang JS; Chen PP; Lin MT; Qian MZ; Lin HX; Chen XP; Chen YC; Jiang B; Chen YJ; Chen WJ; Wang N; Zhou ZM; Gan SR
    J Neurol Sci; 2018 Jul; 390():111-114. PubMed ID: 29801869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
    Graham RK; Slow EJ; Deng Y; Bissada N; Lu G; Pearson J; Shehadeh J; Leavitt BR; Raymond LA; Hayden MR
    Neurobiol Dis; 2006 Feb; 21(2):444-55. PubMed ID: 16230019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominance and homozygosity.
    Zlotogora J
    Am J Med Genet; 1997 Feb; 68(4):412-6. PubMed ID: 9021013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington disease in a 9-year-old boy: clinical course and neuropathologic examination.
    Wojaczyńska-Stanek K; Adamek D; Marszał E; Hoffman-Zacharska D
    J Child Neurol; 2006 Dec; 21(12):1068-73. PubMed ID: 17156701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis.
    Alonso ME; Yescas P; Rasmussen A; Ochoa A; Macías R; Ruiz I; Suástegui R
    Clin Genet; 2002 Jun; 61(6):437-42. PubMed ID: 12121351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature.
    Gonzalez-Alegre P; Afifi AK
    J Child Neurol; 2006 Mar; 21(3):223-9. PubMed ID: 16901424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.
    Ruocco HH; Bonilha L; Li LM; Lopes-Cendes I; Cendes F
    J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):130-5. PubMed ID: 17615168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation.
    Squitieri F; Cannella M; Sgarbi G; Maglione V; Falleni A; Lenzi P; Baracca A; Cislaghi G; Saft C; Ragona G; Russo MA; Thompson LM; Solaini G; Fornai F
    Mech Ageing Dev; 2006 Feb; 127(2):217-20. PubMed ID: 16289240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAG mutation effect on rate of progression in Huntington's disease.
    Squitieri F; Cannella M; Simonelli M
    Neurol Sci; 2002 Sep; 23 Suppl 2():S107-8. PubMed ID: 12548366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.
    Aziz NA; Jurgens CK; Landwehrmeyer GB; ; van Roon-Mom WM; van Ommen GJ; Stijnen T; Roos RA
    Neurology; 2009 Oct; 73(16):1280-5. PubMed ID: 19776381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
    Mariani LL; Tesson C; Charles P; Cazeneuve C; Hahn V; Youssov K; Freeman L; Grabli D; Roze E; Noël S; Peuvion JN; Bachoud-Levi AC; Brice A; Stevanin G; Durr A
    JAMA Neurol; 2016 Sep; 73(9):1105-14. PubMed ID: 27400454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inherited CAG.CTG allele length is a major modifier of somatic mutation length variability in Huntington disease.
    Veitch NJ; Ennis M; McAbney JP; ; Shelbourne PF; Monckton DG
    DNA Repair (Amst); 2007 Jun; 6(6):789-96. PubMed ID: 17293170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
    Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
    Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of Huntington disease.
    Kay C; Hayden MR; Leavitt BR
    Handb Clin Neurol; 2017; 144():31-46. PubMed ID: 28947124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygosity for CCTG mutation in myotonic dystrophy type 2.
    Schoser BG; Kress W; Walter MC; Halliger-Keller B; Lochmüller H; Ricker K
    Brain; 2004 Aug; 127(Pt 8):1868-77. PubMed ID: 15231584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the role of relative telomere length and CAG expansion on initial symptoms of juvenile Huntington disease.
    PerezGrovas-Saltijeral A; Ochoa-Morales A; Jara-Prado A; Velázquez-Cruz R; Rivera-Paredez B; Dávila-OrtizdeMontellano D; Benítez-Alonso EO; Santamaría-Olmedo M; Sevilla-Montoya R; Marfil-Marín E; Valdés-Flores M; Martínez-Ruano L; Camacho-Molina A; Hidalgo-Bravo A
    Eur J Neurol; 2023 Mar; 30(3):612-621. PubMed ID: 36421025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chorea Huntington: a rare case with childhood onset.
    Gencik M; Hammans C; Strehl H; Wagner N; Epplen JT
    Neuropediatrics; 2002 Apr; 33(2):90-2. PubMed ID: 12075490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.